home / stock / kpti / kpti news


KPTI News and Press, Karyopharm Therapeutics Inc. From 10/27/21

Stock Information

Company Name: Karyopharm Therapeutics Inc.
Stock Symbol: KPTI
Market: NASDAQ
Website: karyopharm.com

Menu

KPTI KPTI Quote KPTI Short KPTI News KPTI Articles KPTI Message Board
Get KPTI Alerts

News, Short Squeeze, Breakout and More Instantly...

KPTI - Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021

Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , Oct. 27, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI...

KPTI - Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome

Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome PR Newswire NEWTON, Mass. , Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage p...

KPTI - Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls

Karyopharm Therapeutics has been on my watch list for several years. Sadly, my buy conditions never manifested for me to establish a position. Now I am looking for an entry. I believe Karyopharm’s current valuation along with its upside potential will eventually bring in some b...

KPTI - Karyopharm cut to underweight at JP Morgan citing prospects of XPOVIO

Karyopharm Therapeutics (KPTI -8.0%) lost more than 20% on Thursday, the most since February 2019 after the company’s Q2 2021 revenue lagged analyst expectations. Driven by the lead compound XPOVIO (selinexor), the product revenue rose ~8.5% YoY to $20.2M compared to ~$18.6M in Q2 2020...

KPTI - Karyopharm Therapeutics inc (KPTI) Q2 2021 Earnings Call Transcript

Image source: The Motley Fool. Karyopharm Therapeutics inc (NASDAQ: KPTI) Q2 2021 Earnings Call Aug 5, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics inc (KPTI) Q2 2021 Earnings Call Transcr...

KPTI - Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q2 2021 Results - Earnings Call Transcript

Karyopharm Therapeutics Inc. (KPTI) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Joe Rayne - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Shah - Chief M...

KPTI - Karyopharm Therapeutics Inc. 2021 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Karyopharm Therapeutics Inc. 2021 Q2 - Results - Earnings Call Presentation

KPTI - Profound Medical, STAAR Surgical leads healthcare gainers; Inogen, Karyopharm Therapeutics among major losers

Gainers: Profound Medical (NASDAQ:PROF) +28%, STAAR Surgical (NASDAQ:STAA) +19%, AdaptHealth (NASDAQ:AHCO) +17%, Flora Growth (NASDAQ:FLGC) +16%, Invacare (NYSE:IVC) +15%. Losers: Inogen (NASDAQ:INGN) -32%, Karyopharm Therapeutics (NASDAQ:KPTI) ...

KPTI - BioNTech, Robinhood Markets, Roku among premarket losers' pack

Fastly FSLY -23% on Q2 earnings release  Karyopharm Therapeutics KPTI -18% on Q2 earnings release  Fiverr International FVRR -17% on Q2 earnings release Etsy ETSY -13% on Q2 earnings release Maxar Technologies MAXR -13% on Q2 earning...

KPTI - Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results

Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results -- Achieved Second Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First Half of 2020 -- -- ...

Previous 10 Next 10